Antibiotics for cystic fibrosis may cause hearing loss: study

Image
Press Trust of India New York
Last Updated : Feb 25 2017 | 3:02 PM IST
High dosage of a powerful class of antibiotics administered to treat cystic fibrosis may significantly increases the risk of permanent hearing loss, a new study has warned.
Cystic fibrosis (CF) is an inherited life-threatening disorder that damages the lungs and digestive system. About 70,000 people worldwide are living with the disease.
The study by researchers from Oregon Health & Science University in the US suggests physicians who treat patients with cystic fibrosis may be able to consider alternative strategies for treating the symptoms of respiratory infections associated with CF, especially if patients are responsive to different classes of antibiotics.
"Preventing or ameliorating the effects of permanent hearing loss is crucial for patients with CF who already have a significantly compromised quality of life due to the disease," researchers said.
The medical records of 81 CF patients, aged 15 to 63 years was examined. These patients were further grouped into four quartiles based on the cumulative dosage of aminoglycoside antibiotics administered intravenously.
Researchers found that the two highest dosage groups were 4.79 times more likely to experience permanent hearing loss than the two quartiles with the lowest cumulative dosage exposure.
"This information will allow both the patient and the physician to discuss possible modifications to the treatment regimen, particularly if an alternative approach is or becomes available," researchers said.
"People don't realise the trauma of hearing loss until after they've lost it," said Peter Steyger, a PhD in the OHSU School of Medicine who lost hearing as a child after being treated with antibiotics for a case of meningitis at age 14 months.
"Helen Keller said, 'Blindness separates people from things; deafness separates people from people.' It can lead to isolation, depression and cognitive decline," he added.
The study was published in the Journal of Cystic Fibrosis.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 25 2017 | 3:02 PM IST

Next Story